Organization
Department of Oncology, National Taiwan University Hospital
43 abstracts
3 posters
Abstract
Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR‑mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC).Org: Medical Oncology, Yale School of Medicine, Yale Cancer Center, Department of Thoracic Surgery and Oncology, National Cancer Center Hospital East, Kashiwa, Japan,
Abstract
Detection of circulating tumor DNA following neoadjuvant chemotherapy and surgery to anticipate early relapse in ER positive and HER2 negative breast cancer: Analysis from the PENELOPE-B trial.Org: Royal Cancer Hospital, Heidelberg University, Department of Oncology, National Taiwan University Hospital, Asan Medical Center, Service de Oncología Médica,
Abstract
An age-specific pooled analysis of trastuzumab deruxtecan (T‑DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) from DESTINY-Breast01, -02, and -03.Org: University Hospital Leuven, International Breast Cancer Centre (IBCC), Quironsalud Group, Aichi Cancer Center Hospital, Vall d’Hebron University Hospital/VHIO,
Abstract
Remote symptom-monitoring of patients with advanced lung cancer: A Danish national randomized controlled trial—The ProWide study.Org: Regional Hospital West Jutland, Denmark, Rigshospitalet, Copenhagen, AmbuFlex/WestChronic,
Abstract
Phase III randomized clinical trial comparing the efficacy of neoadjuvant chemotherapy and standard treatment in patients with locally advanced colon cancer: The NeoCol trial.Org: Danish Colorectal Cancer Center South, Vejle Hospital, Gastro Unit, Department of Oncology, National Taiwan University Hospital, Department of Oncology and Palliative Units,
Abstract
ATTRACTION-5: A phase 3 study of nivolumab plus chemotherapy as postoperative adjuvant treatment for pathological stage III (pStage III) gastric or gastroesophageal junction (G/GEJ) cancer.Org: Shizuoka Cancer Center, National Cancer Center Hospital East, Kashiwa, Japan, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea, Beijing Cancer Hospital, Department of Oncology, National Taiwan University Hospital,
Abstract
Primary retroperitoneal lymph node dissection (RPLND) in seminoma stage IIA-IIC ≤3cm: Combined results of the SWENOTECA (Swedish Norwegian Testicular Cancer Group) and Cologne.Org: St. Olav's University Hospital, Karolinska University Hospital, Institute of Clinical Sciences, Karolinska Institutet, University Hospital UMAS,
Abstract
Patient-reported outcomes (PROs) in primary advanced or recurrent endometrial cancer (pA/rEC) for patients (pts) treated with dostarlimab plus carboplatin/paclitaxel (CP) as compared to CP in the ENGOT-EN6/GOG3031/RUBY trial.Org: Copenhagen University Hospital, Washington University School of Medicine, ModernaTX, Rigshospitalet, Nordic Society of Gynaecologic Oncology–Clinical Trial Unit,
Abstract
Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-5-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: A multicentre, open-label, randomised, controlled, phase 3 trial.Org: Sun Yat-sen University Cancer Centre, Collaborative Innovation Centre for Cancer Medicine, Hunan Cancer Hospital, Department of Radiation Oncology, Affiliated Hospital of Guizhou Medical University,
Abstract
Observation vs. radiotherapy in primary mediastinal B-cell lymphoma patients with complete response to standard immunochemotherapy: The IELSG37 randomized trial.Org: Oncology Institute of Southern Switzerland, Institute of Oncology Research, Università della Svizzera italiana, Bellinzona, Switzerland, University of Southampton,
Abstract
TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) in advanced non-small cell lung cancer (aNSCLC).Org: National Cancer Center Hospital East, Kashiwa, Japan, National Cheng Kung University, Daiichi Sankyo Inc., Taichung Veterans General Hospital, Mayo Clinic,
Abstract
KontRASt-01 update: Safety and efficacy of JDQ443 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (NSCLC).Org: University Hospitals Leuven, Leuven, Belgium, Vall d’Hebron University Hospital/VHIO, Department of Oncology, National Taiwan University Hospital, Peter MacCallum Cancer Centre, Melbourne, Australia, National Cancer Centre Singapore,
Abstract
Results of a tailored multimodal lifestyle follow-up care program focusing on physical activity, nutritional behavior and psychological processes in adolescent and young adult cancer survivors: The CARE for CAYA multicenter, randomized clinical trial.Org: University Cancer Center Hamburg, Universitätsklinikum Hamburg-Eppendorf, University Hospital Bonn, Department of Internal Medicine I, Medical University of Vienna, Campus Luebeck,
Abstract
Clinico-molecular characteristics associated with outcomes in breast cancer patients treated with CDK4/6 inhibitors: Results from the AURORA Molecular Screening Initiative.Org: Université Libre de Bruxelles (ULB), Breast Cancer Translational Research Laboratory J.-C. Heuson, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (ULB), Brussels, Belgium, Breast International Group, Brussels, Belgium, Dana-Farber Cancer Institute, Vall d’Hebron Institute of Oncology (VHIO),
Abstract
Palbociclib plus exemestane with GnRH agonist vs capecitabine in premenopausal patients with HR+/HER2- metastatic breast cancer: Updated survival results of the randomized phase 2 study Young-PEARL.Org: Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul National University Hospital, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea, Department of Hematology-Oncology,
Abstract
Efficacy and safety of the vebreltinib in patients with previously treated, secondary glioblastoma/IDH mutant glioblastoma with PTPRZ1-METFUsion GENe (FUGEN): A randomised, multicentre, open-label, phase II/III trial.Org: Beijing Neurosurgical Institute, Capital Medical University, Department of Neurosurgery, Prince of Wales Hospital, Beijing Tiantan Hospital, The First Affiliated Hospital of Zhengzhou University,
Abstract
Tislelizumab versus placebo combined with induction chemotherapy followed by concurrent chemoradiotherapy and adjuvant tislelizumab or placebo for locoregionally advanced nasopharyngeal carcinoma: Interim analysis of a multicenter, randomized, placebo-controlled, double-blind, phase 3 trial.Org: Sun Yat-sen University Cancer Center, Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Centre, Department of Oncology, National Taiwan University Hospital, Affiliated Hospital of Guizhou Medical University,
Abstract
CLAMP: A phase II prospective study of camrelizumab combined with pegaspargase, etoposide, and high-dose methotrexate in patients with natural killer (NK)/T-cell lymphoma.Org: Cancer Center Clínica Universidad de Navarra, Madrid, Spain, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China,
Abstract
Results from a randomised, open-label trial of a multimodal intervention (exercise, nutrition and anti-inflammatory medication) plus standard care versus standard care alone to attenuate cachexia in patients with advanced cancer undergoing chemotherapy.Org: Cancer Clinic, St. Olavs Hospital, Trondheim University Hospital, Department of clinical and molecular medicine, Faculty of Medicine and Health Sciences,
Abstract
High-dimensional longitudinal immune profiling uncovers a dual role of the CXCL9/CXCR3, CXCL13/CXCR5, and CCL11/CCL3 axis in the coupling of immune-related adverse events to immune checkpoint inhibitor response.Org: CHUV, Lausanne University Hospital, Department of Oncology, National Taiwan University Hospital, University of Lausanne, University Hospital of Lausanne,
Abstract
A novel and uniquely designed bispecific antibody (LBL-024) against PD-L1 and 4-1BB in patients with advanced malignant tumors and neuroendocrine carcinoma: A report of safety and robust efficacy of LBL-024 monotherapy in phase I/II, first-in-human, open-label, multicenter, dose escalation/expansion study.Org: Peking University Cancer Hospital & Institute, Henan Cancer Hospital, Fudan University Shanghai Cancer Center, Fujian Provincial Cancer Hospital, Zhejiang Cancer Hospital,
Abstract
Depicting oncologists' perceptions and knowledge of global disparities in conflicts of interest reporting: The ONCOTRUST-1 study.Org: Faculty of Medical Sciences, University Mohammed VI Polytechnic, National Institute of Oncology. Istenhegyi Géndiagnosztika Private Health Center Oncology Clinic, Evercare Hospital Dhaka, Kenyatta University Teaching,
Abstract
Real-world treatment outcomes in patients with HR+ HER2- advanced breast cancer treated with CDK4/6 inhibitors and endocrine therapy.Org: Military Institute of Medicine-National Research Institute, Department of Oncology, National Taiwan University Hospital, Department of Clinical Oncology, Queen Elizabeth Hospital, Breast Unit, Lower Silesian Oncology Centre,
Abstract
Clinical outcomes of patients with HER2-positive microinvasive breast cancer.Org: Department of Oncology, National Taiwan University Hospital, Asan Medical Center, University of Ulsan College of Medicine, Division of Breast Surgery, Department of Surgery, Oncology and Gastroenterology, University of Padova, Oncology 2, IOV - Istituto Oncologico Veneto IRCCS -IOV,
Abstract
A two-decade trend analysis of in-hospital outcomes and racial/ethnic disparities among hospitalized patients with lung cancer in the United States.Org: Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA, MedStar Union Memorial Hospital, Department of Public Health Sciences, University of Chicago, Department of Dermatology,
Abstract
Disrupting how we recruit to cancer clinical trials.Org: Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Columbia University Medical Center, Montefiore Einstein Cancer Center, Albert Einstein College of Medicine, Department of Biostatistics & Data Science,
Abstract
Genomic landscape and therapeutic implications in advanced solid cancers: KOSMOS-II (KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors, KCSG AL-22-09).Org: Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, National Cancer Center Hospital East, Kashiwa, Japan, Goyang-Si, South Korea, Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy,
Abstract
National and state models for relationships between social vulnerability and mammography rates.Org: Wayne State University School of Medicine, Detroit, MI, Millennium Pharmaceuticals, Department of Oncology, National Taiwan University Hospital, College of Medicine, University of the Philippines - Manila,
Abstract
Colorectal cancer and the heart: Uncovering the beat of racial disparities in MACCE.Org: Landmark Medical Center, New York Medical College, Department of Oncology, National Taiwan University Hospital, Mayo Clinic,
Abstract
Association of socioeconomic status with aggressive end-of-life care in patients with cancer before and during the COVID-19 pandemic.Org: University Health Network (UHN), University of Toronto, Queen's University Belfast, Princess Margaret Cancer Centre, Department of Biostatistics & Data Science,
Abstract
Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06).Org: University of Milan and European Institute of Oncology, IRCCS, Fudan University Shanghai Cancer Center, Division of Medical Oncology, National Cancer Centre of Singapore, National Cancer Center Hospital East, Kashiwa, Japan, Latin American Cooperative Oncology Group (LACOG),
Abstract
Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: Primary results of the phase 3 LAURA study.Org: AstraZeneca, Winship Cancer Institute, Department of Thoracic Oncology, Kanagawa Cancer Center, Kanagawa Cancer Center, Cancer Center Clínica Universidad de Navarra, Madrid, Spain,
Abstract
Phase I/II first-in-human study to evaluate the safety and efficacy of tissue factor-ADC MRG004A in patients with solid tumors.Org: Memorial Sloan Kettering Cancer Center, Fudan University Shanghai Cancer Center, University of California Irvine, the First Affiliated Hospital, Zhejiang, University School of Medicine, Shanghai Medical College, Fudan University,
Abstract
ARC-9: A randomized study to evaluate etrumadenant based treatment combinations in previously treated metastatic colorectal cancer (mCRC).Org: David Geffen School of Medicine at UCLA, University of California, Los Angeles, Seoul National University Hospital, Korea University Anam Hospital, Korea University College of Medicine,
Abstract
Ramucirumab plus paclitaxel as switch maintenance versus continuation of oxaliplatin-based chemotherapy in patients (pts) with advanced HER2-negative gastric or gastroesophageal junction (GEJ) cancer: The ARMANI phase III trial.Org: Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Veneto Institute of Oncology IOV–IRCCS, Azienda Ospedaliero Universitaria Santa Maria della Misericordia, Ospedale Santa Maria delle Croci,
Abstract
Endostar combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone for locoregionally advanced nasopharyngeal carcinoma (LA-NPC): A phase III, prospective, randomised-controlled, multicenter clinical trial.Org: Department of Radiation Oncology, the First Affiliated Hospital of Guangxi Medical University, Nanning, China, Department of Oncology, the Affiliated Hospital of North Sichuan Medical College, Nanchong, China, Department of Oncology, Wuzhou Red Cross Hospital, Wuzhou, China, Department of Radiation Oncology, Hainan General Hospital, Haikou, China, Department of Oncology, Liuzhou People's Hospital, Liuzhou, China,
Abstract
Adjuvant PD-1 blockade with camrelizumab in high-risk locoregionally advanced nasopharyngeal carcinoma (DIPPER): A multicenter, open-label, phase 3, randomized controlled trial.Org: Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer,
Abstract
Tolerability and efficacy of BrECADD versus BEACOPP in advanced stage classical Hodgkin lymphoma: GHSG HD21, a randomized study.Org: University Hospital of Cologne, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), German Hodgkin Study Group (GHSG), Swiss Group for Clinical Cancer Research (SAKK), Department of Internal Medicine III with Hematology,
Abstract
Ivonescimab combined with chemotherapy in patients with EGFR-mutant non-squamous non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor treatment (HARMONi-A): A randomized, double-blind, multi-center, phase 3 trial.Org: Sun Yat-sen University Cancer Center, Guangzhou, China, Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China, Thoracic Medicine Department 1, Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China, Yunnan Cancer Hospital, Kunming, China, Sun Yat-sen University Cancer Center, Guang Zhou, China,
Abstract
SU2C-SARC032: A randomized trial of neoadjuvant RT and surgery with or without pembrolizumab for soft tissue sarcoma.Org: UPMC Hillman Cancer Center, Mayo Clinic Rochester, Melanoma Institute Australia, University of Sydney and Sydney Cancer Centre, Chris O'Brien Lifehouse,
Abstract
A phase Ib study of PI3Kα inhibitor risovalisib mesylate in combination with fulvestrant in patients with PIK3CA-mutated, HR+/HER2- advanced breast cancer.Org: Fudan University Shanghai Cancer Center, The Second Hospital of Dalian Medical University, Harbin Medical University Cancer Hospital, Liaoning Cancer Hospital & Institute, Shenyang, China, Hunan Cancer Hospital,
Abstract
Health-related quality of life (HRQoL) and symptoms in LIBRETTO-431 patients with RET fusion-positive advanced non-small-cell lung cancer (NSCLC).Org: Shanghai Pulmonary Hospital, Shanghai, China, AOU San Luigi, University of Torino, Hospital Ramón y Cajal, University Hospitals KU Leuven,
Abstract
Health-related quality of life (QoL) in randomized phase III trials in oncology: Association between results of QoL, results of primary endpoint and drug approval.Org: Department of Oncology, Ivrea Community Hospital, ASL-TO4, Ivrea (Turin), Italy, Department of Oncology, University of Turin, Città della Salute e della Scienza di Torino, Turin, Italy, Department of Oncology , University of Turin, A.O.Ordine Mauriziano, Turin, Italy, Department of Oncology, University of Turin, AO Ordine Mauriziano, Turin, Italy, Royal Marsden Hospital, Renal and Melanoma Unit, London, United Kingdom,